Access denied. You must login to view this page.
Expert Highlights
Watch as experts George L. Bakris, MD, Rajiv Agarwal, MD, and Janet McGill, MD, discuss additional clinical pearls on DKD progression and the emerging role of novel non-steroidal MRAs for the treatment of DKD
| Interview #1 Evaluating the Risk for DKD ProgressionWatch the experts share some highlights including: - Early recognition and screening for DKD
- Monitoring kidney function
- Risk factors for DKD progression
|
| Interview #2 The Rationale for Non-Steroidal MRAs in DKDWatch the experts share some highlights including: - Differentiating between steroidal and non-steroidal MRAs
- Adverse events and limitations with steroidal MRAs in DKD
- Advantages of finerenone in DKD
- The overview of kidney results of the FIDELIO trial
|
| Interview #3 The Cardiovascular Benefits of FinerenoneWatch the experts share some highlights including: - The interplay between the kidney and heart
- CVD benefits of finerenone: analysis from the FIDELIO trial and ongoing CVD studies with finerenone
- How does finerenone fit within the context of SGLT-2is
|
| Interview #4 Finerenone: Putting the Data Into ContextWatch the experts share some highlights including: - Finerenone in the context of existing treatments
- Clinical pearls for incorporating finerenone to the DKD treatment armamentarium in the near future
|